Septerna Inc/$SEPN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Septerna Inc
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
Ticker
$SEPN
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
75
ISIN
US81734D1046
Website
Septerna Inc Metrics
BasicAdvanced
$467M
-
-$3.89
-
-
Price and volume
Market cap
$467M
52-week high
$11.36
52-week low
$4.66
Average daily volume
1.9M
Financial strength
Current ratio
32.193
Quick ratio
31.71
Long term debt to equity
5.768
Total debt to equity
6.252
Profitability
EBITDA (TTM)
-89.761
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-8,097.03%
Operating margin (TTM)
-9,339.10%
Effective tax rate (TTM)
0.51%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on equity (TTM)
-30.96%
Valuation
Price to revenue (TTM)
218.151
Price to book
1.15
Price to tangible book (TTM)
1.15
Price to free cash flow (TTM)
-2.811
Free cash flow yield (TTM)
-35.58%
Free cash flow per share (TTM)
-373.19%
Growth
Revenue change (TTM)
108.76%
Earnings per share change (TTM)
113.83%
Bulls say / Bears say
Septerna's recent collaboration with Novo Nordisk, valued at up to $2.2 billion, to develop oral treatments for obesity and type 2 diabetes, positions the company favorably in the expanding metabolic disease market (reuters.com).
The company's strong financial position, with $420.8 million in cash and equivalents as of December 31, 2024, provides a solid foundation for ongoing research and development efforts (globenewswire.com).
Septerna's successful IPO in October 2024, which raised $331.2 million and saw shares rise nearly 31% on debut, reflects strong investor confidence in the company's prospects (reuters.com).
The discontinuation of the SEP-786 Phase 1 clinical trial due to elevated unconjugated bilirubin levels raises concerns about the viability of this lead candidate and potential delays in product development (globenewswire.com).
Despite a strong cash position, Septerna reported a net loss of $71.8 million for the full year ended December 31, 2024, highlighting ongoing financial challenges common in biotech firms (globenewswire.com).
The competitive landscape in the biotech sector, particularly in GPCR-targeted therapies, may pose challenges for Septerna in differentiating its products and achieving market penetration.
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
Septerna Inc News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Septerna Inc stock?
Septerna Inc (SEPN) has a market cap of $467M as of June 21, 2025.
What is the P/E ratio for Septerna Inc stock?
The price to earnings (P/E) ratio for Septerna Inc (SEPN) stock is 0 as of June 21, 2025.
Does Septerna Inc stock pay dividends?
No, Septerna Inc (SEPN) stock does not pay dividends to its shareholders as of June 21, 2025.
When is the next Septerna Inc dividend payment date?
Septerna Inc (SEPN) stock does not pay dividends to its shareholders.
What is the beta indicator for Septerna Inc?
Septerna Inc (SEPN) does not currently have a Beta indicator.